Dec 19,2018

AbbVie and Voluntis to develop companion digital therapeutics

Voluntis, a company specialized in digital therapeutics, announced today that it has entered into a collaboration with AbbVie, a research-based global biopharmaceutical company, to enhance patient care coordination in immunology with innovative digital therapeutic software. Together the companies will leverage Voluntis’ proven Theraxium technology to make this new solution available to patients and providers in the United States.

COLLABORATION PARTNERSHIP

#product & service

#software

View Analyst & Ambassador Comments
Go to original news
Nov 28,2018

MindMaze Acquires NMI

Braintech leader MindMaze has today announced an acquisition that aims to significantly advance recovery for patients suffering from neurological diseases and injuries. The acquisition of Neuro Motor Innovations Corporation (NMI), which combines neuroscience and a novel form of animation – “neuroanimation” – to stimulate vast improvement of cognitive and motor functions, complements MindMaze’s current approach to neuro-rehabilitation.

COLLABORATION MERGERS & ACQUISITION

#product & service

#software

View Analyst & Ambassador Comments
Go to original news
May 30,2018

Kaiku Health follow-up algorithm for cancer patients treated with immunotherapy enters a multi-center clinical trial

A novel follow-up algorithm for cancer immunotherapy, developed by digital health company Kaiku Health, is undergoing clinical validation in a multi-center trial conducted at Oulu University Hospital, Turku University Hospital and Docrates Cancer Center in Finland.

PRODUCT

#software

View Analyst & Ambassador Comments
Go to original news
Jan 19,2017

WellDoc Receives FDA 510(k) Clearance to Offer a Non-Prescription Version of BlueStar® Digital Therapeutic for Type 2 Diabetes

Digital health leader WellDoc announced today that the U.S. Food and Drug Administration (FDA) has granted the Company 510(k) class II clearance for a non-prescription version of the BlueStar® digital therapeutic. Based on this clearance, WellDoc will offer BlueStar® and BlueStar® Rx. The non-prescription version will have all the first-in-class features of BlueStar® Rx apart from an insulin calculator.

REGULATORY FDA

#mobile app

#software

View Analyst & Ambassador Comments
Go to original news
Sep 14,2017

Pear Therapeutics gets de novo FDA clearance for reSET, a digital therapeutic for substance abuse

Pear Therapeutics' reSET system for the treatment of substance abuse has been granted a de novo clearance by the FDA. It's the first software-only digital therapeutic the FDA has cleared with claims to improve clinical outcomes in a disease. reSET is a 12-week program designed to treat addiction and dependency on stimulants, cannabis, cocaine, and alcohol. The system is not usable for opioids, but Pear is also seeking clearance for an opioid product called reSET-O.

REGULATORY FDA

#mobile app

#pdt

#software

View Analyst & Ambassador Comments
Go to original news
Nov 06,2017

One Drop Announces Regulatory Approval And Launch In Canada

One Drop today announced Health Canada approval for One Drop | Chrome, its Bluetooth-enabled blood glucose monitoring system that syncs directly with the One Drop | Mobile app. One Drop | Chrome is available as part of One Drop's Premium and Plus subscriptions plans, marrying modern design with evidence-based diabetes management strategies that improve clinical outcomes at a fraction of the cost of current standards of care.

PRODUCT

#mobile app

#software

#coaching

View Analyst & Ambassador Comments
Go to original news
Nov 29,2017

Glytec Integrates With Onduo Virtual Diabetes Clinic

Glytec is pleased to announce its Glucommander™ Outpatient will be integrated with Onduo’s virtual diabetes clinic to help people with type 2 diabetes more easily manage insulin therapy and achieve their glucose targets. The integrated solution will launch in pilot programs with select U.S. providers and payers early 2018.

COLLABORATION PARTNERSHIP

#connected device

#mobile app

#software

View Analyst & Ambassador Comments
Go to original news
Feb 16,2017

Five digital health trends investors are watching in 2017

Skip Fleshman is a partner at Asset Management Ventures who has invested in companies such as Proteus Digital Health, WellDoc, HealthTap, Evidation Health, Reify Health, Lark and Welkin. He shares his insights and opnions ont he digital health trends including digital therapeutics. He pointed interesting companies in this sector target diabetes prevention (Omada Health), Type 2 diabetes (WellDoc), mental health (Pear Therapeutics) and respiratory illness (Propeller Health).

#mobile app

#software

View Analyst & Ambassador Comments
Go to original news
Apr 07,2017

Can “Digital Therapeutics” Be as Good as Drugs?

Digital therapeutics, or “digiceuticals,” as some call them, have become a Holy Grail in some quarters of Silicon Valley, where investors see the chance to deliver medicine through your smartphone. Andreessen Horowitz, the venture firm, even predicts digital drugs will become “the third phase” of medicine, meaning the successor to the chemical and protein drugs we have now, but without the billion-dollar cost of bringing one to market.

#software

#mobile app

View Analyst & Ambassador Comments
Go to original news
May 05,2016

LabStyle Innovations Granted Key Patent in Europe Relating to the Dario™ Diabetes Management Tool

LabStyle Innovations Corp. today announced that it has been granted a key patent by the European Patent Office (EPO) for the company's personalized blood glucose monitoring device. The patent, EP2569622, entitled "FLUID TESTING APPARATUS AND METHODS OF USE," covers claims related to a method and apparatus for performing fluid parameter measurement on a fluid sample via an earphone socket on a mobile phone. The EPO decision to grant was reached on April 7, 2016, and the patent became effective on May 4, 2016.

PRODUCT

#mobile app

#software

View Analyst & Ambassador Comments
Go to original news
Subscribe to SOFTWARE